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Abstract
Objective The objective of this study is to examine the
diurnal variability of C-reactive protein (CRP) in obstruc-
tive sleep apnea (OSA).
Methods and measurements Participants included44women
and men with untreated OSA (mean apnea/hypopnea index=
37.5, SD±28) and 23 healthy adults with no OSA. Sleep was
monitored with polysomnography in the University of
California San Diego General Clinical Research Center. Over
a 24-h period, blood was collected every 2 h, and CRP levels
were determined.
Results Adjusting for age, gender, and body mass index, a
significant group by time interaction showed that patients
with OSA had higher CRP levels during the daytime
(8:00 a.m.–8:00 p.m.) versus the nighttime (10:00 p.m.
until 6:00 p.m.; p<0.001). Non-apneics showed no signifi-
cant change in CRP levels during the 24 h.
Conclusions The findings indicate that sleep apnea patients
have disproportionately elevated CRP levels in the day ver-
sus the nighttime, possibly as a result of carryover effects of
nighttime arousal into the daytime.
Keywords Obstructivesleepapnea.C-reactiveprotein.
Diurnalvariability
Introduction
Inflammation is a hallmark of the pathophysiology of
obstructive sleep apnea (OSA) and represents a pathway
linking OSA to increased cardiovascular morbidity [1-3].
C-reactive protein (CRP) is an acute phase response protein
implicated in broad range of cardiovascular diseases [4].
Through its effects on adhesion molecules and mononucle-
ar cell recruitment and adhesion [5, 6], CRP plays an
important role in atherosclerosis development [7].
Independent of age and body mass index (BMI), CRP
levels are found to be elevated in OSA and associated with
severity of apnea as indexed by the apnea/hypopnea index
(AHI) [8-11], although not all studies demonstrate this
relationship [12]. These studies of CRP and OSA have
relied on a single blood sample obtained in the morning or
afternoon hours to determine CRP levels, with few, if any,
utilizing multiple blood sampling to examine the diurnal
variation of CRP in OSA.
Studies in healthy individuals have not demonstrated a
diurnal variation of CRP. Meier-Ewert et al., for example,
determined CRP concentrations in hourly blood samples in
13 healthy individuals and found no rhythmic diurnal
variation over a 24-h period [13]. Of relevance to OSA are
studies examining the effects of sleep disruption and/or
deprivation on CRP levels. In 43 otherwise healthy women,
Okun et al. showed that elevated CRP levels (single
samples obtained anywhere between the hours of 10:00 a.
m. and 4:00 p.m.) were associated with self-reported sleep
disruptions [14]. Laboratory studies of sleep deprivation
report inconsistent findings. Frey et al. studied the effects of
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CRP every 30 min revealed a significant decrease in CRP
in morning levels (between the hours of 9:00 a.m. and
11:00 a.m.) and in late night levels (between the hours of
11:00 p.m. and 12:00 a.m.) [15] .M e i e r - E w e r te ta l .
examined the effects of extended (88 h) and partial (4 h)
sleep deprivation on CRP levels in ten healthy individuals;
blood sampling every 60 to 90 min revealed that sleep
deprivation was associated with marked elevation of daily
averages of CRP levels [16]. In contrast to these studies,
Dimitrov et al. using an 8-h sleep deprivation in 15 healthy
individuals with blood sampling every 1.5 or 3 h showed
no effects on CRP levels [17]. Thus, it is fair to say that the
literature is not consistent concerning effects of sleep
disruption on CRP.
The purpose of this study is to examine the diurnal
pattern of CRP in individuals with OSA and to compare
that pattern to that observed in otherwise healthy individ-
uals with normal sleep.
Materials and methods
Forty-four women and men with untreated OSA and 23
healthy adults with no OSA were recruited by advertising
and word of mouth referral. Participants were excluded if
they reported a history of major medical illnesses (other
than OSA and hypertension), current psychiatric diagnoses,
or if they were receiving psychotropic medication. Patients
who were receiving anti-hypertensive medications had their
medications tapered for 3 weeks prior to participation. The
protocol was approved by the University of California San
Diego (UCSD) Human Subjects Committee. After descrip-
tion of the study, written informed consent was obtained.
Participants arrived at the UCSD General Clinical
Research Center Gillin Laboratory of Sleep and Chronobi-
ology (GCRC-GLSC) at 5:00 p.m., at which time, a venous
catheter was inserted. Starting at 6:00 p.m., a blood sample
was collected every 2 h for the next 24 h. Blood samples
were collected in ethylenediaminetetraacetic acid, placed on
ice, spun in a refrigerated centrifuge, and the plasma was
stored at −80°C until assayed. CRP was assayed by using
the high sensitivity Denka-Seiken assay [18]. The assay’s
intra-assay coefficient of variation (CV) is <1.0%, the inter-
assay CV is 1.6%, and the sensitivity is <0.05 mg/l. To
minimize intra-assay variance, all 12 samples from a
participant were analyzed in the same run.
Starting at 8:00 p.m. the following evening (i.e.,
upon completion of the 24-h blood sampling), partic-
ipants were instrumented for standard polysomnography
[19]. Lights were out at 10:00 p.m., and recording
continued until 7:00 a.m. Polysomnography records
were scored by trained sleep technicians for total sleep
time, total minutes spent awake after sleep onset
(WASO), and apneas and hypopneas. Apneas were
defined as decrements in airflow of ≥90% from baseline
for ≥10 s. Hypopneas were defined as decrements in
airflow of ≥50% but <90% from baseline for ≥10 s. The
numbers of apneas and hypopneas per hour of sleep
were calculated to obtain the AHI. A diagnosis of OSA
was given if AHI ≥10.
Statistical analysis
Means and standard deviations or frequencies were calculated
for demographic and apnea-related variables. Subject charac-
teristicsdatawerecomparedbetweenapneicsandnon-apneics
by one-way analysis of variance for continuous variables and
chi-squared tests for categorical variables. Box-plots and
histograms were used to examine distributions of CRP
levels. Line-plots of CRP levels over a 24-h period for each
subject were also graphed to assess trends in marker levels.
Based on these graphs, we used a linear mixed-effects model
approach to characterize the time-course of CRP levels over
the 24-h period. These models were fitted with restricted
maximum likelihood methods [20]. This modeling strategy
was adopted because it is a flexible approach that can
account for correlations between repeated measures on
an individual, include patient-specific intercept and
slope terms (referred to as random effects), adjust for
potentially confounding covariates (referred to as fixed-
effects), and allow for unbalanced data (i.e., different
individuals can have different numbers of observations).
Regarding unbalanced data, four participants did not
have all 12 CRP data points (one OSA patient had nine,
one OSA patient had ten, one control had nine, and one
control had 11).
The model included a random effect at the patient level
(random interceptterminthe model)toallowfor variabilityin
initial CRP levels between individuals. The following
covariates (fixed-effects) were also included in the models:
OSA status (present versus absent: reference was participant’s
without OSA), time (12 time points at the 2-h intervals with
the analysis starting at the 10:00 p.m. time point), and
potential confounders (age, BMI, and gender). Two separate
models were run, one with time as a continuous variable and
the other with time as a categorical night versus day variable.
A likelihood ratio test was used to test the significance of the
interaction between time and OSA status to assess whether
profiles of CRP levels over the day varied by OSA status.
Residual plots and quantile–quantile plots were used to assess
adequacy offit of the models. Data were analyzed using the R
statistics software package (http://cran.stat.ucla.edu). CRP
values were log-transformed prior to analysis to better
approximate a Gaussian distribution. Statistical significance
was set at p<0.05.
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Sample characteristics
Sample characteristics are presented in Table 1. The OSA
group was older (F=5.1, p<0.05), had a greater BMI (F=
5.23, p<0.5), as well as higher systolic (F=15.1, p<0.001)
and diastolic (F=4.43, p<0.05) blood pressure. By defini-
tion, the AHI index was greater in those with OSA (F=20.8,
p<0.001). OSA patients spent approximately 44.5 fewer
minutes asleep (F=13.3, p<0.01). There was a marginally
significant group difference for WASO (F=3.54, p=0.065),
with OSA patients spending more time awake after the onset
of sleep. Unadjusted mean 24-h CRP levels were marginally
higher in sleep apneics (t=1.91, p=0.06). We also examined
correlations between (log-transformed) CRP levels and AHI
among all participants. Across the 12 individual CRP time
points, correlations with AHI ranged from a low of r=0.26
(p=0.10) at the 8:00 p.m. time point to a high of r=0.34(p=
0.04) at the 4:00 p.m. time point. The mean CRP value
correlated with AHI at r=0.28, p≤0.05.
Diurnal rhythm
TheCRPlevels throughoutthe dayaregraphedinFigs.1 and 2
according to group. Model results, including regression
coefficients, slope, and p values, are presented in Table 2 for
the two models that were fit. Model I was a mixed model
starting time at 10:00 p.m. with time as a continuous variable.
There were significant main effects of BMI (with higher BMI
being associated with higher CRP levels; regression coeffi-
cient = 0.094, p<0.001) and gender (with CRP levels being
somewhat higher in women; regression coefficient = 0.667, p=
0.04) for the 24-h period. There was not a significant main
effect (p=0.27) or interaction (p=0.13) for OSA group status.
Model II, also starting with the 10:00 p.m. sample,
had time as categorical variable, with night from
10:00 p.m. to 6:00 a.m. and day from 8:00 a.m. to
8:00 p.m. In addition to the same main effects for BMI
and gender, a significant group by time interaction
Table 1 Sample characteristics
Variables (mean±SD) OSA No OSA
Number 44 23
Age (years)
a 50.4 (8) 46.1 (7.5)
Body mass index (kg/m
2)
a 30.4 (5.4) 27.4 (4.3)
Gender (number of women) 9 9
Systolic blood pressure (mm Hg)
b 132.9 (18.6) 116.6 (11.6)
Diastolic blood pressure (mm Hg)
a 78.8 (9.5) 74.0 (8.2)
Number of cigarette smokers 6 5
Apnea/hypopnea index
b 37.5 (28.8) 4.78 (3.1)
Total sleep time (hours)
b 6.17 (.74) 6.86 (.50)
Wake after sleep onset (minutes) 53.9 (24.9) 39.4 (29.2)
ap<0.05
bp<0.01
OSA Controls
Nighttime Daytime 
Time in hours (10:00pm – 8:00pm) 
Fig. 1 Individual participant’s 24-h CRP levels in OSA and healthy
controls every 2 h starting at 10:00 p.m., with daytime denoted as
8:00 a.m. until 8:00 p.m. and nighttime denoted as 10:00 p.m. until
6:00 a.m.
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Fig. 2 Unadjusted 24-h CRP levels in OSA and healthy controls
every 2 h starting at 10:00 p.m. (mean±SEM). In an analysis adjusting
for age, gender, and body mass index, patients with sleep apnea were
found to have higher CRP levels during the daytime (8:00 a.m. until
8:00 p.m.) versus the nighttime (10:00 p.m. until 6:00 a.m.; p<0.001);
whereas, non-apneics showed no significant change in CRP levels
during the 24 h
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the apneic group, mean CRP levels were higher during the
day than at night (p<0.001). There were no significant
differences in day versus night CRP levels for the group
with no sleep apnea.
We also conducted several sensitivity analyses to assess
the adequacy of our fitted models. First, systolic and
diastolic blood pressure, as well as smoking status were
added to the mixed-effects models and were not signifi-
cantly associated with CRP levels and did not change the
observed association between OSA and 24-h CRP levels. In
other sensitivity analyses, we also fitted cosinor models
[21] which are a well-established method for modeling
sleep-wake circadian rhythms. Residual plots and Akaike
information criteria indicated that the cosinor models did
not fit the CRP data well, as would be expected given the
reasonably stable CRP levels during the 24-h period
evidenced in line-plots, especially among non-apneics.
Discussion
CRP is an important risk factor and biomarker for
cardiovascular diseases [4-7]. Prior studies using morning
or afternoon sampling found CRP to be elevated in
individuals with OSA compared to non-OSA adults [8-
11]. We found 24-h mean CRP levels to be marginally
higher in the patients with OSA. By obtaining samples
every 2 h during the 24-h period, we were able to
demonstrate a diurnal difference in CRP levels in OSA,
with daytime levels being significantly higher than night-
time levels. We observed this interaction in an analytic
model with time as a categorical night versus day variable
and not an analytic model with time as a continuous
variable. We suspect that the categorical analysis, when the
two groups had the maximum difference in CRP levels,
gave us the best power to discern the interaction. The p
value of the interaction for the time as a continuous variable
was p=0.13, and with a larger sample-size, a significant
interaction might have emerged.
OSA is characterized by repeated disruptions of sleep.
More periodic sleep disruptions, as assessed by subjective
report, have been associated with elevated CRP levels [14].
Studies of more significant sleep disruption, i.e., sleep
deprivation, report conflicting findings on CRP levels,
including a decrease [15], increase [16], and no change [17]
in CRP levels. Consistent with one prior study to examine
this issue, we found no evidence of diurnal variation of
CRP in healthy individuals not experiencing disrupted sleep
[13], raising the question whether it is the disturbed sleep
associated with apneas and hypopneas in OSA patients or
some other characteristic of apnea patients that is the
responsible for the effect on CRP diurnal rhythm.
A limitation of this study is that we characterized night
as starting at 10:00 p.m. (when the lights were turned off in
the GCRC-GLSC) and ending at 6:00 a.m. This definition
of night would not have universally applied to the night/day
schedule for all of the participants.
What mechanisms might underlie the effect of OSA on
inducing a diurnal rhythm of CRP? Sleep disruption and
partial sleep deprivation are both associated with sympa-
thetic activation [22, 23]. Sleep apneics show elevated
norepinephrine levels as compared to non-apneics [24]. The
repeated disruption of sleep as determined by the number of
apneic events and/or the severity of nocturnal hypoxia are
directly associated with the elevated norepinephrine levels
[25-27]. Some of the earliest observations with catechol-
amines indicated that nighttime sympathetic over-activity in
OSA carried over to the daytime when apnea events were
not occurring [26, 28]. Elevations in catecholamines are
Beta slope Std. Error t-Statistic p value
Model I (time modeled as a continuous linear variable)
Age 0.0202 0.016 1.285 0.20
BMI 0.094 0.025 3.770 <0.001
Gender 0.667 0.312 2.140 0.04
OSA group 0.328 0.294 1.115 0.27
Time 0.001 0.003 0.168 0.87
Time by OSA interaction 0.006 0.004 1.522 0.13
Model II (time modeled as a categorical day versus night variable)
Age 0.020 0.016 1.285 0.20
BMI 0.094 0.025 3.770 <0.001
Gender 0.667 0.312 2.140 0.04
OSA group 0.316 0.294 1.077 0.29
Daytime/nighttime −0.020 0.024 −0.806 0.43
Daytime/nighttime by OSA interaction 0.081 0.030 2.738 0.01
Table 2 Mixed-effects model
results
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adrenergic receptors triggering CRP biosynthesis and
release [29, 30]. Another possible mechanism is inflamma-
tory cytokines. CRP synthesis in the liver is controlled by
interleukin-6 (IL-6) as well as by tumor necrosis factor-alpha
(TNF-α)[ 31]. A study by Entzian et al. in OSA reported no
evidence of circadian rhythm change in ex vivo levels of IL-
6 from cultured blood samples [32], although studies do
indicate that circulating IL-6 levels are elevated in OSA [33].
Entzian et al. did report that the circadian rhythm of ex vivo
TNF-α was disturbed in OSA such that the nocturnal
physiologic peaks were absent but that an additional daytime
peak was evident [32]. Thus, in addition to catecholamines,
an additional potential mechanism of our findings is an effect
of OSA on the diurnal rhythm of TNF-α.
What might be the significance of greater daytime than
nighttime CRP levels in OSA? Studies link elevations in
daytime CRP with other markers of increased cardiovascu-
lar risk, including with greater nighttime blood pressure
variability and with non-dipping of blood pressure [34, 35].
Studies in OSA show increased risk for cardiovascular
events in the daytime, and this risk is attributed to several
mechanisms, including local and systemic inflammation
[36, 37]. Regardless, our data suggests that in order to
better understand inflammatory variables in OSA, fine-
grained chronobiological analyses with frequent blood
sampling will be invaluable.
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